title: From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.
authors.affiliation: Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec, Canada.
authors.forename: C K
authors.initials: CK
authors.lastname: Lau
authors.forename: W C
authors.initials: WC
authors.lastname: Black
authors.forename: M
authors.initials: M
authors.lastname: Belley
authors.forename: C
authors.initials: C
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Charleson
authors.forename: D
authors.initials: D
authors.lastname: Denis
authors.forename: J Y
authors.initials: JY
authors.lastname: Gauthier
authors.forename: R
authors.initials: R
authors.lastname: Gordon
authors.forename: D
authors.initials: D
authors.lastname: Guay
authors.forename: P
authors.initials: P
authors.lastname: Hamel
authors.forename: S
authors.initials: S
authors.lastname: Kargman
authors.forename: Y
authors.initials: Y
authors.lastname: Leblanc
authors.forename: J
authors.initials: J
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Ouellet
authors.forename: D
authors.initials: D
authors.lastname: Percival
authors.forename: P
authors.initials: P
authors.lastname: Prasit
authors.forename: P
authors.initials: P
authors.lastname: Roy
authors.forename: K
authors.initials: K
authors.lastname: Skorey
authors.forename: P
authors.initials: P
authors.lastname: Tagari
authors.forename: P
authors.initials: P
authors.lastname: Vickers
authors.forename: E
authors.initials: E
authors.lastname: Wong
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D002351:Carrageenan / Q000633:toxicity; D002860:Chromium Radioisotopes; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D004064:Digestive System / Q000187:drug effects; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005243:Feces / Q000737:chemistry; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D007213:Indomethacin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D007527:Isoenzymes / Q000187:drug effects*; D008565:Membrane Proteins; D008968:Molecular Conformation; D015394:Molecular Structure; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D051381:Rats; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002860:Chromium Radioisotopes; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D009363:Neoplasm Proteins; C109337:L 748780; D002351:Carrageenan; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496513:Ptgs1 protein, rat; D007213:Indomethacin